Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Feb;2(1):62-70.
doi: 10.1111/j.1752-4571.2008.00063.x.

Cancer research meets evolutionary biology

Affiliations

Cancer research meets evolutionary biology

John W Pepper et al. Evol Appl. 2009 Feb.

Abstract

There is increasing evidence that Darwin's theory of evolution by natural selection provides insights into the etiology and treatment of cancer. On a microscopic scale, neoplastic cells meet the conditions for evolution by Darwinian selection: cell reproduction with heritable variability that affects cell survival and replication. This suggests that, like other areas of biological and biomedical research, Darwinian theory can provide a general framework for understanding many aspects of cancer, including problems of great clinical importance. With the availability of raw molecular data increasing rapidly, this theory may provide guidance in translating data into understanding and progress. Several conceptual and analytical tools from evolutionary biology can be applied to cancer biology. Two clinical problems may benefit most from the application of Darwinian theory: neoplastic progression and acquired therapeutic resistance. The Darwinian theory of cancer has especially profound implications for drug development, both in terms of explaining past difficulties, and pointing the way toward new approaches. Because cancer involves complex evolutionary processes, research should incorporate both tractable (simplified) experimental systems, and also longitudinal observational studies of the evolutionary dynamics of cancer in laboratory animals and in human patients. Cancer biology will require new tools to control the evolution of neoplastic cells.

Keywords: acquired drug resistance; cancer progression; drug development; natural selection; neoplasms; somatic evolution; stem cells; transdisciplinary research.

PubMed Disclaimer

References

    1. Adams JM, Strasser A. Is tumor growth sustained by rare cancer stem cells or dominant clones? Cancer Research. 2008;68:4018–4021. - PubMed
    1. Alain T, Kim M, Johnston RN, Urbanski S, Kossakowska AE, Forsyth PA, Lee PW. The oncolytic effect in vivo of reovirus on tumour cells that have survived reovirus cell killing in vitro. British Journal of Cancer. 2006;95:1020–1027. - PMC - PubMed
    1. Boehm T, Folkman J, Browder T, O'Reilly MS. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature. 1997;390:404–407. - PubMed
    1. Bursch W, Ellinger A, Kienzl H, Torok L, Pandey S, Sikorska M, Walker R, et al. Active cell death induced by the anti-estrogens tamoxifen and ICI 164 384 in human mammary carcinoma cells (MCF-7) in culture: the role of autophagy. Carcinogenesis. 1996;17:1595–1607. - PubMed
    1. Cairns J. Mutation selection and the natural history of cancer. Nature. 1975;255:197–200. - PubMed

LinkOut - more resources